IN8bio (Nasdaq: INAB) announced that CEO and co-founder William Ho will present at the TD Cowen 46th Annual Health Care Conference on March 2, 2026 at 9:50 am ET in Boston. The company will host one-on-one investor meetings March 2-4.
A live webcast and replay will be available via the company’s Events and Presentations page at https://investors.in8bio.com.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – INAB
+2.65%
6 alerts
+2.65%Session close to close
+6.6%Peak in 5 hr 58 min
$16.80MMarket Cap
0.3xRel. Volume
In the Feb 24 session, INAB gained 2.65%, reflecting a moderate positive market reaction.
Argus tracked a peak move of +6.6% during that session.
Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility.
This announcement centers on IN8bio’s participation in the TD Cowen 46th Annual Health Care Conferen...
Analysis
This announcement centers on IN8bio’s participation in the TD Cowen 46th Annual Health Care Conference on March 2, 2026, offering a platform to highlight recent achievements and upcoming milestones. Against a backdrop of shares trading well below the $2.32 200-day MA and far under the 52-week high, investors may watch for any new strategic or clinical details revealed in the presentation or subsequent one-on-one meetings.
Key Figures
Conference date:March 2, 2026Presentation time:9:50 am ETConference duration:March 2–4, 2026
3 metrics
Conference dateMarch 2, 2026IN8bio presentation at TD Cowen 46th Annual Health Care Conference
Presentation time9:50 am ETScheduled time for IN8bio company presentation
Conference durationMarch 2–4, 2026TD Cowen 46th Annual Health Care Conference dates
Key Terms
gamma-delta (γδ) t cell therapies
1 terms
gamma-delta (γδ) t cell therapiesmedical
"developing innovative gamma-delta (γδ) T cell therapies for cancer and autoimmune diseases"
A type of immunotherapy that uses a special subset of white blood cells called gamma-delta (γδ) T cells to find and kill infected or cancerous cells. Unlike most immune cells that need a specific ID badge to spot targets, these cells recognize stressed or abnormal cells more broadly, which could allow for off-the-shelf or more widely usable treatments. Investors care because successful γδ T‑cell therapies could alter drug pipelines, company valuations, and the competitive landscape for cancer and infectious disease treatments.
NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies for cancer and autoimmune diseases, today announced that William Ho, CEO and co-founder, will be presenting at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, at 9:50 am ET.
William Ho will be giving a company presentation highlighting IN8bio’s latest achievements and upcoming milestones. The conference, to be held March 2-4, 2026, in Boston, will also include one-on-one investor meetings hosted by members of management.
A live webcast and replay link for the TD Cowen conference can be found here, and will be available under "Events and Presentations" in the News & Presentations section of the IN8bio website at https://investors.in8bio.com.
About IN8bio
IN8bio is a clinical-stage biopharmaceutical company developing γδ T cell therapeutic and γδ T cell engager (TCE) product candidates to address unmet medical needs. γδ T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company's lead programs consist of INB-100, an allogeneic γδ T cell candidate for adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation. The Company is also developing INB-200/400, an autologous genetically modified γδ T cell candidate for newly diagnosed Glioblastoma (GBM). The preclinical pipeline includes a novel γδ T cell engager platform, INB-600, which activates and expands γδ T cells in vivo for deep target cell depletion and is being developed for oncology and autoimmune indications. For more information about IN8bio, visit www.IN8bio.com.
When will IN8bio (INAB) present at the TD Cowen 2026 conference?
IN8bio will present on March 2, 2026 at 9:50 am ET, with one-on-one meetings March 2-4. According to IN8bio, CEO William Ho will deliver the company presentation and outline recent progress and upcoming milestones for INAB.
How can investors watch IN8bio (INAB) presentation at TD Cowen on March 2, 2026?
Investors can watch via a live webcast and later replay on IN8bio’s website. According to IN8bio, the webcast and replay will be posted under the Events and Presentations section at https://investors.in8bio.com.
What will IN8bio (INAB) CEO William Ho cover during the March 2, 2026 presentation?
William Ho will highlight the company’s latest achievements and upcoming milestones for IN8bio’s programs. According to IN8bio, the presentation will focus on clinical progress in gamma-delta T cell therapies and near-term corporate developments.
Will IN8bio (INAB) hold investor meetings at the TD Cowen conference in March 2026?
Yes, IN8bio management will host one-on-one investor meetings March 2-4, 2026 in Boston. According to IN8bio, members of management will be available for investor meetings alongside the scheduled company presentation.
Where is the TD Cowen 46th Annual Health Care Conference taking place for IN8bio’s March 2026 presentation?
The TD Cowen conference is being held in Boston, March 2-4, 2026, with IN8bio presenting March 2 at 9:50 am ET. According to IN8bio, the event includes presentations and one-on-one investor meetings.
Does IN8bio (INAB) provide a replay of its TD Cowen 2026 presentation online?
Yes, a replay will be available on the company website under Events and Presentations. According to IN8bio, the live webcast and replay link will be posted at https://investors.in8bio.com following the presentation.
